DFJ Frontier joins Prolacta second-round funding
Oct 4, 2006

Sacramento Business Journal

DFJ Frontier is one of several investors that participated in Prolacta Bioscience's series B financing round, netting Prolacta more than $5 million in private venture funding.

DFJ, with offices in Sacramento and Santa Barbara, has invested in Prolacta before. DFJ, and affiliate of Draper Fisher Jurvetson, typically invests in seed and early-stage technology companies, usually taking a significant stake in the first round of funding and becoming actively involved on the board of directors.

The funding will allow Monrovia-based Prolacta to complete studies that show the benefits of feeding premature and critically ill infants with 100 percent human milk. The privately held company focuses on the nutritional needs of underweight, premature and critically ill infants, particularly in the first 30 days of life.

Other Prolacta investors include Arcturus Capital, DFJ Mercury, Philip Capital, Funk Ventures Capital, the Gideon Hixon Fund, Draper Richards, and Draper Associates